Mankind Pharma has announced the resignation of S.R. Batliboi & Co. LLP as statutory auditor for its subsidiary, Bharat Serums and Vaccines Limited. The departure is purely procedural, mandated by Insolvency and Bankruptcy Code regulations following the subsidiary's voluntary liquidation approved on September 7, 2026. The auditor completed the fiscal 2026 audit, and the resignation, effective September 28, 2026, does not suggest any financial or governance irregularities within the entity.
Mankind Pharma Auditor Resigns Following Subsidiary Liquidation
Resignation effective September 28, 2026; Auditor completed FY26 audit May 12, 2026.
Reader Takeaway: Procedural resignation triggered by liquidation regulations; no impact on financial reporting or internal governance.
What just happened
Mankind Pharma Limited has officially notified the stock exchanges that S.R. Batliboi & Co. LLP has resigned as the statutory auditor for its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSV). The resignation is effective from September 28, 2026.
Why this matters
The resignation is a mandatory administrative step. Following the resolution on September 7, 2026, to initiate voluntary liquidation for BSV under the Insolvency and Bankruptcy Code (IBC), 2016, a liquidator is legally barred from appointing any professional who served as the company's auditor in the preceding five years. Consequently, the firm stepped down to ensure compliance with the Insolvency and Bankruptcy Board of India regulations.
The backstory
Mankind Pharma clarified that S.R. Batliboi & Co. LLP concluded the statutory audit for the financial year ended March 31, 2026, on May 12, 2026. The firm has not initiated any audit work for the current fiscal year ending March 31, 2027. The company explicitly confirmed there are no material concerns or disagreements behind this departure.
What to track next
Investors should monitor future BSE filings regarding the progress of the voluntary liquidation of BSV and any subsequent impacts on Mankind Pharma’s consolidated financial structure as the process moves forward under the appointed liquidator.